… Objective/Rationale:  Mitochondrial dysfunction has been proposed as a key feature … small molecule inhibitors of Bid and Drp-1, and siRNA targeting regulators of mitochondrial integrity are applied in … translational approaches in the near future. Anticipated Outcome:  The proposed study provides novel insights into …

… Parkinson’s research.     Stuart Isaacson, MD, director of Parkinson’s Disease and Movement Disorders Center of … find research opportunities and how to choose the right study for you.  The panelists also … podcast .  Christina Destro Associate Director Research Communications …

… in Parkinson’s disease (PD). Alpha synuclein is also known to be the major constituent of a signature patholological … for microRNAs 7 and 153. These two microRNAs have been shown to reduce alpha-synuclein levels in culture. We will … in which alpha synuclein accumulates. Anticipated Outcome: We expect to learn the following: Can we successfully …

… Study Rationale:  Mitochondria are energy-generating structures vital to the … this study, we will examine a new drug mechanism that has shown neuroprotection in preclinical models of PD. This drug … like pathology with SBT-272. We will determine whether the compound affects measures of PD symptoms that are clinically …

… in Parkinson’s disease (PD). Alpha synuclein is also known to be the major constituent of a signature patholological … for microRNAs 7 and 153. These two microRNAs have been shown to reduce alpha-synuclein levels in culture. We will … in which alpha synuclein accumulates. Anticipated Outcome:  We expect to learn the following: Can we successfully …

… We're often advocating for investigators to make de-identified data and biosamples from clinical … Medicine , for example, Foundation leaders wrote about how such practice could aid in discovery and replication of … quality data for sharing with peers, the broader scientific community and the public; by increased data circulation and …